EDAP to Present at Piper Sandler 37th Annual Healthcare Conference

EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, is set to present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025. The company's Chief Executive Officer, Ryan Rhodes, alongside Chief Financial Officer Ken Mobeck, will not only deliver a presentation but also host one-on-one investor meetings, providing an opportunity for deeper engagement with stakeholders and analysts.

The presentation is scheduled to take place from 10:30 to 10:55 AM ET as part of a fireside discussion format, which aims to foster an informal yet informative dialogue around EDAP’s advancements and strategic direction. This format allows attendees to gain insights into the company’s growth plans and innovative technologies, particularly its cutting-edge medical devices.

EDAP specializes in developing sophisticated, minimally invasive medical solutions utilizing ultrasound technology, with a focus on urological applications. The company’s Focal One® platform stands out as a leading prostate focal therapy, marking a significant advancement in targeted cancer treatment, and there are ongoing endeavors to explore its applicability for other medical conditions as well.

The conference will be held at The Lotte New York Palace, and interested parties can access a live webcast of the presentation through the company’s investor relations website. This event serves as a pivotal moment for EDAP to showcase its innovative strategies and potential market impact, further establishing its position within the healthcare sector.

For those seeking further details or to reach out for investor relations inquiries, EDAP TMS provides contact information through their investor relations channel, including connections with LifeSci Advisors for additional support.

EDAP TMS SA (NASDAQ: EDAP) is poised for a notable presentation at the upcoming Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The event will showcase EDAP's advancements in robotic energy-based therapies, a rapidly evolving sector in minimally invasive medical technologies. As the company continues to solidify its leadership in this space with products like the Focal One®, interest from investors is likely to be substantial.

From a market perspective, investors should consider several factors prior to the conference. EDAP's innovative solutions in ultrasound technology, particularly in prostate cancer treatment, have shown potential for expansion into other indications, which could drive future revenue growth. The strategic fireside discussion format could allow management to address key investor concerns while elaborating on pathways for market expansion.

Furthermore, hosting one-on-one investor meetings signifies EDAP’s commitment to transparent communication with its stakeholders. This setting provides an excellent opportunity for institutional investors to gain deeper insights directly from company leadership, which can influence stock performance post-conference.

Benchmarking EDAP against its competitors in the healthcare and robotics sectors can provide additional context. If management can effectively communicate their value proposition and growth strategies, EDAP's stock may see an upward trajectory.

Additionally, monitoring the market's reaction to emerging trends in healthcare technology and investor sentiment around robotics will be crucial. Given the increasing adoption of minimally invasive procedures due to their efficiency and reduced recovery times, EDAP appears well-positioned to capitalize on favorable market dynamics.

In conclusion, investors should closely follow the outcomes of EDAP's presentation and the feedback received during the conference, as these could provide valuable indicators of the company's potential growth and market positioning.